Lund, SE — September 8, 2025 — Leads & Copy — Alligator Bioscience (Nasdaq Stockholm:ATORX) announced that an investigator-initiated randomized Phase 2/3 clinical trial will evaluate mitazalimab in combination with FOLFOX chemotherapy in previously treated biliary tract cancer. The trial, led by Prof. Cindy Neuzillet and Dr. Matthieu Delaye of Institut Curie, with Unicancer as the study sponsor, will investigate mitazalimab’s potential in an additional tumor type with significant unmet medical need. First patient enrollment is expected in the second quarter of 2026, with the initial part of the study enrolling 112 patients across 30 sites in France.
Søren Bregenholt, CEO at Alligator Bioscience, expressed pleasure at the launch of the new project and underscored the scientific and clinical relevance of targeting CD40 in biliary tract cancer. Prof. Cindy Neuzillet of Institut Curie, Principal Investigator of the trial, stated that the CROCOBIL study will investigate if the combination of mitazalimab with FOLFOX could overcome resistance to first-line chemo-immunotherapy in advanced biliary tract cancer.
Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. Unicancer is a French hospital network dedicated to the fight against cancer.
Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00
Source: Alligator Bioscience
